chronic obstructive pulmonary disease
Conditions
Interventions
After receiving a diagnosis of COPD that indicated inhaler therapy, the patient was immediately interviewed by the pharmacist, who assessed the patient'
s ability to use an inhaler considering factors such as inhalation, grip and hearing and his or her understanding of what is required, as well as the patient'
s expectations and preferences, and practical considerations such as device portability, the need for visual and auditory confirmation of successful inhalation, daily dose frequency and medication cos
Sponsors
Kyoto-Katsura Hospital, Department of Parmacy
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Eligible patients were those with stable COPD, defined as the presence of a post-bronchodilator forced expiratory volume in 1 s (FEV1) of <70% and confirmation from the physician that they were clinically stable.
Exclusion criteria
Exclusion criteria: The study excluded any patients who had undergone pneumonectomy or who had dementia and could not be provided with caregiving support for inhaler therapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint was the change in FEV1 between baseline and the end of the study period at 26 weeks. | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary endpoints were safety and the changes in the scores for the three scales, which was the COPD Assessment Test (CAT) ,the modified British Medical Research Council Dyspnoea Scale (mMRC), Adherence Starts with Knowledge-20 (ASK-20). | — |
Countries
Japan
Contacts
Public ContactEiji Shiwaku
Kyoto-Katsura Hospital Department of Pharmacy
Outcome results
None listed